These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

839 related articles for article (PubMed ID: 23860502)

  • 1. Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease.
    Angulo P; Bugianesi E; Bjornsson ES; Charatcharoenwitthaya P; Mills PR; Barrera F; Haflidadottir S; Day CP; George J
    Gastroenterology; 2013 Oct; 145(4):782-9.e4. PubMed ID: 23860502
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Noninvasive fibrosis tools in NAFLD: validation of APRI, BARD, FIB-4, NAFLD fibrosis score, and Hepamet fibrosis score in a Portuguese population.
    Rigor J; Diegues A; Presa J; Barata P; Martins-Mendes D
    Postgrad Med; 2022 May; 134(4):435-440. PubMed ID: 35332833
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Accuracy of Noninvasive Scoring Systems in Assessing Risk of Death and Liver-Related Endpoints in Patients With Nonalcoholic Fatty Liver Disease.
    Hagström H; Nasr P; Ekstedt M; Stål P; Hultcrantz R; Kechagias S
    Clin Gastroenterol Hepatol; 2019 May; 17(6):1148-1156.e4. PubMed ID: 30471458
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identifying Nonalcoholic Fatty Liver Disease Advanced Fibrosis in the Veterans Health Administration.
    Patel YA; Gifford EJ; Glass LM; Turner MJ; Han B; Moylan CA; Choi S; Suzuki A; Provenzale D; Hunt CM
    Dig Dis Sci; 2018 Sep; 63(9):2259-2266. PubMed ID: 29779083
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease.
    McPherson S; Stewart SF; Henderson E; Burt AD; Day CP
    Gut; 2010 Sep; 59(9):1265-9. PubMed ID: 20801772
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Large-scale long-term follow-up study of Japanese patients with non-alcoholic Fatty liver disease for the onset of hepatocellular carcinoma.
    Kawamura Y; Arase Y; Ikeda K; Seko Y; Imai N; Hosaka T; Kobayashi M; Saitoh S; Sezaki H; Akuta N; Suzuki F; Suzuki Y; Ohmoto Y; Amakawa K; Tsuji H; Kumada H
    Am J Gastroenterol; 2012 Feb; 107(2):253-61. PubMed ID: 22008893
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histological Evaluation of Non-alcoholic Fatty Liver Disease and Its Correlation with Different Noninvasive Scoring Systems with Special Reference to Fibrosis: A Single Center Experience.
    Rath MM; Panigrahi MK; Pattnaik K; Bhuyan P; Kar SK; Misra B; Misra D; Meher C; Agrawal O; Rath J; Singh SP
    J Clin Exp Hepatol; 2016 Dec; 6(4):291-296. PubMed ID: 28003718
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The NAFLD Decompensation Risk Score: External Validation and Comparison to Existing Models to Predict Hepatic Events in a Retrospective Cohort Study.
    Ahmed HS; Gangasani N; Jayanna MB; Long MT; Sanchez A; Murali AR
    J Clin Exp Hepatol; 2023; 13(2):233-240. PubMed ID: 36950488
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Noninvasive scoring systems in patients with nonalcoholic fatty liver disease with normal alanine aminotransferase levels.
    Yoneda M; Imajo K; Eguchi Y; Fujii H; Sumida Y; Hyogo H; Ono M; Suzuki Y; Kawaguchi T; Aoki N; Sata M; Kanemasa K; Kohgo Y; Saibara T; Chayama K; Itoh Y; Yoshikawa T; Anzai K; Fujimoto K; Okanoue T; Nakajima A;
    J Gastroenterol; 2013 Sep; 48(9):1051-60. PubMed ID: 23184095
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Portal Venous Pulsatility Index: A Novel Biomarker for Diagnosis of High-Risk Nonalcoholic Fatty Liver Disease.
    Baikpour M; Ozturk A; Dhyani M; Mercaldo ND; Pierce TT; Grajo JR; Samir AE
    AJR Am J Roentgenol; 2020 Apr; 214(4):786-791. PubMed ID: 31939698
    [No Abstract]   [Full Text] [Related]  

  • 11. Are simple noninvasive scoring systems for fibrosis reliable in patients with NAFLD and normal ALT levels?
    McPherson S; Anstee QM; Henderson E; Day CP; Burt AD
    Eur J Gastroenterol Hepatol; 2013 Jun; 25(6):652-8. PubMed ID: 23325287
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Accuracy of Noninvasive Fibrosis Scores to Detect Advanced Fibrosis in Patients With Type-2 Diabetes With Biopsy-proven Nonalcoholic Fatty Liver Disease.
    Singh A; Gosai F; Siddiqui MT; Gupta M; Lopez R; Lawitz E; Poordad F; Carey W; McCullough A; Alkhouri N
    J Clin Gastroenterol; 2020; 54(10):891-897. PubMed ID: 32168133
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Validation study of systems for noninvasive diagnosis of fibrosis in nonalcoholic fatty liver disease in Latin population.
    Pérez-Gutiérrez OZ; Hernández-Rocha C; Candia-Balboa RA; Arrese MA; Benítez C; Brizuela-Alcántara DC; Méndez-Sánchez N; Uribe M; Chávez-Tapia NC
    Ann Hepatol; 2013; 12(3):416-24. PubMed ID: 23619258
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modified thresholds for fibrosis risk scores in nonalcoholic fatty liver disease are necessary in the obese.
    Ooi GJ; Burton PR; Doyle L; Wentworth JM; Bhathal PS; Sikaris K; Cowley MA; Roberts SK; Kemp W; O'Brien PE; Brown WA
    Obes Surg; 2017 Jan; 27(1):115-125. PubMed ID: 27220852
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Suboptimal performance of simple noninvasive tests for advanced fibrosis in Chinese patients with nonalcoholic fatty liver disease.
    Xun YH; Fan JG; Zang GQ; Liu H; Jiang YM; Xiang J; Huang Q; Shi JP
    J Dig Dis; 2012 Nov; 13(11):588-95. PubMed ID: 23107446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence and Predictors of Nonalcoholic Fatty Liver Disease in Family Members of Patients With Nonalcoholic Fatty Liver Disease.
    Anand A; Singh AA; Elhence A; Vaishnav M; Biswas S; Gunjan D; Gamanagatti SR; Nayak B; Kumar R; Shalimar
    J Clin Exp Hepatol; 2022; 12(2):362-371. PubMed ID: 35535086
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States.
    Kim D; Kim WR; Kim HJ; Therneau TM
    Hepatology; 2013 Apr; 57(4):1357-65. PubMed ID: 23175136
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-alcoholic fatty liver disease (NAFLD) fibrosis score predicts 6.6-year overall mortality of Chinese patients with NAFLD.
    Xun YH; Guo JC; Lou GQ; Jiang YM; Zhuang ZJ; Zhu MF; Luo Y; Ma XJ; Liu J; Bian DX; Shi JP
    Clin Exp Pharmacol Physiol; 2014 Sep; 41(9):643-9. PubMed ID: 24837195
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease.
    Shah AG; Lydecker A; Murray K; Tetri BN; Contos MJ; Sanyal AJ;
    Clin Gastroenterol Hepatol; 2009 Oct; 7(10):1104-12. PubMed ID: 19523535
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic Accuracy of Noninvasive Fibrosis Models to Detect Change in Fibrosis Stage.
    Siddiqui MS; Yamada G; Vuppalanchi R; Van Natta M; Loomba R; Guy C; Brandman D; Tonascia J; Chalasani N; Neuschwander-Tetri B; Sanyal AJ;
    Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1877-1885.e5. PubMed ID: 30616027
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.